Canaccord Genuity Maintains Buy on Exagen, Lowers Price Target to $10
Benzinga Newsdesk 7 months ago
NewsPrice TargetAnalyst Ratings
Canaccord Genuity analyst Kyle Mikson maintains Exagen (NASDAQ:XGN) with a Buy and lowers the price target from $15 to $10.
Canaccord Genuity analyst Kyle Mikson maintains Exagen (NASDAQ:XGN) with a Buy and lowers the price target from $15 to $10.